BPC 157 Peptide Evidence and Regulatory Status

The bpc 157 peptide has no approval from the Food and Drug Administration (FDA) for any medical condition, and completed human trials evaluating its clinical efficacy do not exist. At Longevity Benchmark, we review clinical trial registries and federal regulatory records to separate published scientific facts from unverified wellness marketing. The molecule is a synthetic pentadecapeptide. It contains a sequence of fifteen amino acids. Researchers originally derived this peptide sequence from a protein found in gastric juice.

Where the BPC 157 Peptide Stands with the FDA

The FDA does not approve BPC-157 for any human medical indication, clinical application, or pharmaceutical drug formulation. There is no approved human drug product containing BPC-157 on the United States commercial market. Federal regulatory documentation checked through 22 April 2026 provides no clinical safety clearance for this substance.

Marketing materials asserting official endorsement or legal pharmaceutical status contradict federal records. Consumers cannot legally obtain BPC-157 as an approved prescription medicine or legitimate over-the-counter therapeutic product.

The Federal Compounding Withdrawn Substance List

Federal compounding policies exclude BPC-157 from permitted bulk drug substance lists because the original nominators formally withdrew their submissions. On the official regulatory docket, federal authorities categorize BPC-157 under bulk drug substances nominated but withdrawn by nominators. Placement on the withdrawn list does not mean the substance received formal clearance.

It also does not mean the agency assigned it to active Category 2 restriction lists. Instead, the nominators withdrew their submissions. Consequently, compounding pharmacies receive no legal allowance to prepare formulations containing the substance under standard compounding rules.

Several other research peptides share this withdrawn compounding status. These substances include CJC-1295, epitalon, injectable GHK-Cu, and melanotan II. The list also contains MOTS-c, PEG-MGF, selank acetate, semax, thymosin alpha-1, and the thymosin beta-4 fragment TB-500. Readers can review these regulatory boundaries in our guide to peptide therapy FDA status rules.

Current Human Clinical Trials on the BPC 157 Peptide

ClinicalTrials.gov, the NIH registry, records four human studies involving BPC-157, and none has published completed efficacy results for any therapeutic indication. In October 2015, sponsor PharmaCotherapia d.o.o. initiated NCT02637284, a Phase 1 pilot study in 42 healthy volunteers. The trial intended to measure safety and pharmacokinetics of PCO-02. Primary completion occurred in February 2016. However, the study status is listed as unknown, and researchers posted no clinical data.

Ten years later, a second study emerged. On 2 February 2026, sponsor Hudson Biotech commenced NCT07437547, a randomized, double-blind, placebo-controlled Phase 2 trial. The investigation aims to enroll 120 participants to assess accelerated repair of acute grade II hamstring strains confirmed by magnetic resonance imaging. That trial remains actively recruiting, with a primary completion target set for 14 February 2027.

A third trial, designated NCT07803250, is sponsored by the University of Arkansas. This Phase 1 trial plans to evaluate the impact of BPC-157 on recovery from rotator cuff repair surgery in 30 participants. The study protocol lists a start date of 1 January 2027 and estimated primary completion on 1 August 2027. It is currently not yet recruiting.

A fourth registry record, NCT07752381, represents a completed 40-participant study sponsored by Parlay Wellness. That study examined a commercial peptide gummy product registered as a dietary supplement. It did not evaluate BPC-157 as a regulated pharmaceutical drug. Across the entire national registry, no completed, results-posted human trial validates the therapeutic claims made across online retail storefronts.

Structural Distinctions Between Peptides and Anabolic Steroids

BPC-157 is a short synthetic peptide and does not possess the chemical architecture of an anabolic steroid. It is a pentadecapeptide: fifteen linked amino acids.

BPC-157 itself replicates a fragment of a gastric juice protein. However, being distinct from steroids does not make the compound safe or approved for medical consumption.

Federal documentation provides no clinical safety clearance or approval status for BPC-157. Being a peptide rather than a steroid says nothing about whether it is safe; only completed safety data would.

Scientific Limitations of Oral Administration Claims

Published human clinical investigations have not established that BPC-157 functions effectively or safely when taken orally.

The scientific literature provides no completed human clinical trials confirming efficacy for any marketed use. The early Phase 1 trial, NCT02637284, planned to measure safety and pharmacokinetics in 42 healthy volunteers. That trial never published its findings. The registry lists its status as unknown.

Furthermore, the completed 40-person study, NCT07752381, examined a commercial gummy product as a dietary supplement rather than an approved pharmaceutical. A dietary supplement study does not evaluate drug bioavailability or therapeutic efficacy under federal drug standards. Because regulators have approved no medical product containing BPC-157, no verified oral formulation or standardized delivery method exists. Other experimental peptides face similar absorption questions, as detailed in our analysis of KPV peptide evidence and our review of DSIP peptide evidence.

Patient Populations Who Should Avoid the BPC 157 Peptide

Individuals managing tendon tears, ligament injuries, or chronic inflammatory diseases should avoid purchasing unverified research peptides. Patients recovering from orthopedic surgery require therapies supported by human clinical trials.

Individuals seeking verified tendon or muscle repair must avoid gray-market compounds and work with licensed orthopedists. Cost considerations regarding peptide therapies are detailed in our breakdown of peptide therapy cost factors.

Clinical Evidence Requirements to Alter the Verdict

Our editorial verdict on BPC-157 will change only when randomized, double-blind, placebo-controlled trials publish conclusive efficacy and safety data in peer-reviewed journals. The ongoing Phase 2 hamstring strain trial, NCT07437547, represents the primary study that could alter this clinical assessment. That trial aims to evaluate 120 patients with MRI-confirmed acute grade II hamstring injuries. It holds a primary completion target of 14 February 2027.

If that trial completes successfully and demonstrates statistically significant tissue healing without adverse events, human efficacy will have its first registered verification. Similarly, the proposed University of Arkansas rotator cuff repair study, NCT07803250, could add preliminary Phase 1 surgical recovery data. That study is slated for completion in August 2027. Until investigators publish completed data from these registered protocols, the peptide remains an unproven experimental substance. We apply this exact standard across other compounds, including our evaluations of Dihexa evidence and PT-141 evidence.

Clinical Alternatives for Musculoskeletal Recovery

Buying and using a research peptide on your own means no clinician is checking the injury, the product, or the result. Consulting a qualified clinician ensures that recovery protocols rely on verified science rather than commercial marketing claims surrounding the bpc 157 peptide.

Related

• Peptide therapy FDA status and Category 2 compounding rules
• Peptide therapy cost breakdown and clinic pricing factors
• KPV peptide evidence evaluation and regulatory standing
• DSIP peptide scientific review and human research limits
• Dihexa cognitive research evidence and clinical reality
• PT-141 peptide approval status and clinical indication data